Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT01452139
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 102 participants
- Registry
-
NCT01452139
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT01452139. Randomized; single masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
- Acronym
- RAPID STEMI
- Condition
- STEMI
- Intervention (Genetic)
- Point-of-Care Genetic Testing
- Intervention (Drug)
- Prasugrel
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Collaborator
- Spartan Bioscience Inc.
Record details
- Record id
cardio:ct-nct01452139- Content hash
013bd568bc2f023ed06e5b2739d6291206a1b741a1fa93b218e3bb5978f16cd0